Resveratrol and Sirolimus in Lymphangioleiomyomatosis Trial

Inclusion Criteria:

Subjects enrolled in the trial must meet all of the following criteria.

1. Definitive diagnosis LAM based on the presence of characteristic cystic change on
high-resolution computed tomography (HRCT) of the chest. The diagnosis must be
confirmed by one of the following:

A) Histopathological confirmation by biopsy (lung, abdominal mass, lymph node or
kidney or cytology from thoracic or abdominal sources revealing human melanoma
black-45 (HMB45)+ staining of spindled/epithelioid cells) B) Compatible chest CT scan
findings in the setting of tuberous sclerosis, angiomyolipomas (diagnosed by CT,
magnetic resonance imaging (MRI) by the site radiologist or biopsy) or chylous pleural
effusion (verified by tap) C) Chest CT scan findings compatible with LAM and a VEGF-D
level ≥ 800pg/ml.

2. Age 18 years or greater.

3. Signed and dated informed consent

4. Currently on sirolimus for treatment of LAM for at least 20 weeks

5. Evidence of disease stabilization on sirolimus as demonstrated by two stable values of
serum VEGF-D post initiation of sirolimus drawn at least 12 weeks apart from each
other. For the purpose of this study, a variation in serum VEGF-D of less than or
equal to 15% is considered stable.

Exclusion Criteria:

- Subjects who meet any of the following criteria are not eligible for enrollment as
study participants:

1. Known allergy or hypersensitivity to Resveratrol

2. Inability to provide informed consent

3. Active enrollment in other clinical drug trials for LAM

4. Pregnant or plan to become pregnant in the next 6 months

5. Breast feeding

6. Inability to comply with pulmonary function tests or follow up visits

7. Inadequate contraception

8. Use of estrogen containing medications within the 30 days prior to randomization

9. History of organ transplant

10. Actively listed for lung transplantation

11. Inability to comply with study procedures or attend scheduled study visits

12. Any clinically significant medical disease (other than LAM) that is associated
with an expected survival of less than 2 years, or likely to impact the ability
of the patient to participate in the study in the opinion of the investigator, or
impact the study efficacy or safety assessments.